Literature DB >> 27624297

The treatment of hyperinsulinemic hypoglycaemia in adults: an update.

M V Davi1, A Pia2, V Guarnotta3, G Pizza4, A Colao4, A Faggiano5.   

Abstract

BACKGROUND: Treatment of hyperinsulinemic hypoglycaemia (HH) is challenging due to the rarity of this condition and the difficulty of differential diagnosis. The aim of this article is to give an overview of the recent literature on the management of adult HH.
METHODS: A search for reviews, original articles, original case reports between 1995 and 2016 in PubMed using the following keywords: hyperinsulinemic hypoglycaemia, insulinoma, nesidioblastosis, gastric bypass, autoimmune hypoglycaemia, hyperinsulinism, treatment was performed.
RESULTS: One hundred and forty articles were selected and analysed focusing on the most recent treatments of HH.
CONCLUSIONS: New approaches to treatment of HH are available including mini-invasive surgical techniques and alternative local-regional ablative therapy for benign insulinoma and everolimus for malignant insulinoma. A correct differential diagnosis is of paramount importance to avoid unnecessary surgical operations and to implement the appropriate treatment mainly in the uncommon forms of HH, such as nesidioblastosis and autoimmune hypoglycaemia.

Entities:  

Keywords:  Autoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment

Mesh:

Year:  2016        PMID: 27624297     DOI: 10.1007/s40618-016-0536-3

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  139 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Increased vulnerability of newly forming beta cells to cytokine-induced cell death.

Authors:  J J Meier; R A Ritzel; K Maedler; T Gurlo; P C Butler
Journal:  Diabetologia       Date:  2005-12-02       Impact factor: 10.122

3.  Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.

Authors:  Anne-Sophie Dussol; Marie-Odile Joly; Cecile Vercherat; Julien Forestier; Valérie Hervieu; Jean-Yves Scoazec; Catherine Lombard-Bohas; Thomas Walter
Journal:  Cancer       Date:  2015-06-08       Impact factor: 6.860

4.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

5.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Authors:  Geoffrey J Service; Geoffrey B Thompson; F John Service; James C Andrews; Maria L Collazo-Clavell; Ricardo V Lloyd
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

Review 6.  Autoimmune forms of hypoglycemia.

Authors:  Beatrice C Lupsa; Angeline Y Chong; Elaine K Cochran; Maria A Soos; Robert K Semple; Phillip Gorden
Journal:  Medicine (Baltimore)       Date:  2009-05       Impact factor: 1.889

7.  Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Authors:  N C Turner; S J Strauss; D Sarker; R Gillmore; A Kirkwood; A Hackshaw; A Papadopoulou; J Bell; I Kayani; C Toumpanakis; F Grillo; A Mayer; D Hochhauser; R H Begent; M E Caplin; T Meyer
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

Review 8.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871

9.  Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma.

Authors:  M L Healy; S J Dawson; R M L Murray; J Zalcberg; M Jefford
Journal:  Intern Med J       Date:  2007-06       Impact factor: 2.048

10.  Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma.

Authors:  Jianpeng Chen; Caixia Wang; Junqing Han; Yi Luan; Yangang Cui; Rong Shen; Dan Sha; Lei Cong; Zheng Zhang; Weibo Wang
Journal:  Expert Rev Anticancer Ther       Date:  2013-04-10       Impact factor: 4.512

View more
  9 in total

Review 1.  Non-surgical ablative therapies for inoperable benign insulinoma.

Authors:  C Mele; A Brunani; B Damascelli; V Tichà; L Castello; G Aimaretti; M Scacchi; P Marzullo
Journal:  J Endocrinol Invest       Date:  2017-07-28       Impact factor: 4.256

Review 2.  Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

Authors:  Xi-Feng Jin; Matilde P Spampatti; Christine Spitzweg; Christoph J Auernhammer
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 3.  Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE.

Authors:  Shejil Kumar; Mariah Melek; Peter Rohl
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-24       Impact factor: 6.055

Review 4.  Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

Authors:  Francesca Spada; Roberta E Rossi; Elda Kara; Alice Laffi; Sara Massironi; Manila Rubino; Franco Grimaldi; Sherrie Bhoori; Nicola Fazio
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-04

5.  Endoscopic ultrasound-guided ethanol ablation therapy for pancreatic insulinoma: an unusual strategy.

Authors:  Adriana de Sousa Lages; Isabel Paiva; Patrícia Oliveira; Francisco Portela; Francisco Carrilho
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-04-06

6.  Adult Nesidioblastosis in Chronic Kidney Disease.

Authors:  Eduardo Lozano-Melendez; Mercedes Aguilar-Soto; Luis Eugenio Graniel-Palafox; Laura Elena Ceceña-Martínez; Rafael Valdez-Ortiz; Fabio Solis-Jimenez
Journal:  Case Rep Endocrinol       Date:  2019-02-14

Review 7.  Exendin-4 analogs in insulinoma theranostics.

Authors:  Tom J P Jansen; Sanne A M van Lith; Marti Boss; Maarten Brom; Lieke Joosten; Martin Béhé; Mijke Buitinga; Martin Gotthardt
Journal:  J Labelled Comp Radiopharm       Date:  2019-08       Impact factor: 1.921

8.  Clarithromycin and Glipizide Drug-drug Interaction Leading to Refractory Hypoglycemia.

Authors:  Xu Cong Ruan; Poh Yong Tan; Yuyang Tan
Journal:  Cureus       Date:  2019-06-02

9.  Nationwide survey of endogenous hyperinsulinemic hypoglycemia in Japan (2017-2018): Congenital hyperinsulinism, insulinoma, non-insulinoma pancreatogenous hypoglycemia syndrome and insulin autoimmune syndrome (Hirata's disease).

Authors:  Yuki Yamada; Kana Kitayama; Maki Oyachi; Shinji Higuchi; Rie Kawakita; Yutaka Kanamori; Tohru Yorifuji
Journal:  J Diabetes Investig       Date:  2019-12-24       Impact factor: 4.232

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.